Announced Mon, 10 Aug · 17:37 IST

Q1 FY27 results: Revenue up 56% YoY, PAT jumps 10x to Rs 111 lakh

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-0.9%1-day move

₹74.70

prior close

₹84.90

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-5.8-8.1-12.1-8.4-0.9-5.9-2.3-5.8-4.4-2.3————

Up moveDown movePending

AI summary

Concord Drugs reported strong Q1 FY27 results. Standalone revenue rose 56% YoY to about Rs 20.9 crore, with PAT surging to Rs 1.11 crore from Rs 11 lakh in Q1 FY26. EBITDA margins expanded from around 7% to about 11%. QoQ revenue declined due to seasonality versus a strong Q4. EPS improved to Rs 0.84 from Rs 0.11 despite a 33% rise in equity base from a recent preferential issue. Consolidated numbers are similar. Limited review by Pundarikashyam and Associates was clean with no qualifications.

Likely market impact

Strong YoY growth in revenue and profit signals healthy momentum. EPS rising despite share dilution is a positive for shareholders.